Year archive

RELIEF Therapeutics Holding AG — 2023 filings

All 59 regulatory filings released by RELIEF Therapeutics Holding AG (RLF) in 2023, sourced directly from the official regulator.

59 Filings

2023 Period

2023 filings (59)

Filing	Released	Lang
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth Legal Proceedings Report	2023-12-05	English
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth Regulatory Filings	2023-12-05	English
Relief Therapeutics Announces CEO Transition Board/Management Information	2023-11-22	English
Relief Therapeutics Announces CEO Transition Board/Management Information	2023-11-22	English
Relief Therapeutics Announces that more than 400,000 of its ADRs are currently outstanding and that, as a result, the Company has achieved an Important NASDAQ Initial Listing Milestone Delisting Announcement	2023-10-10	English
Relief Therapeutics Announces that more than 400,000 of its ADRs are currently outstanding and that, as a result, the Company has achieved an Important NASDAQ Initial Listing Milestone Share Issue/Capital Change	2023-10-10	English
Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update Report Publication Announcement H1 2023	2023-09-15	English
Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update Earnings Release H1 2023	2023-09-15	English
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference Regulatory Filings	2023-09-01	English
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference Regulatory Filings	2023-09-01	English
Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVATM (ACER-001) with Acer Therapeutics Regulatory Filings	2023-08-30	English
Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA™ (ACER-001) with Acer Therapeutics M&A Activity	2023-08-30	English
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE in the U.S. with Pentec Health M&A Activity	2023-07-19	English
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health M&A Activity	2023-07-19	English
Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE in the Middle East Regulatory Filings	2023-06-23	English
RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement Share Issue/Capital Change	2023-06-23	English
Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE® in the Middle East Regulatory Filings	2023-06-23	English
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders AGM Information	2023-06-20	English
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders AGM Information	2023-06-20	English
RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement Capital/Financing Update	2023-06-16	English
RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement Capital/Financing Update	2023-06-16	English
RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of Shareholders AGM Information	2023-05-26	English
RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of Shareholders AGM Information	2023-05-26	English
Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory Regulatory Filings	2023-05-15	English
Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory Regulatory Filings	2023-05-15	English
Relief Therapeutics Has Filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission Report Publication Announcement FY 2022	2023-05-12	English
Relief Therapeutics Has Filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission Report Publication Announcement	2023-05-12	English
Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares Share Issue/Capital Change	2023-05-03	English
Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares Share Issue/Capital Change	2023-05-03	English
Relief Therapeutics Announces Collaboration Partner Reports OLPRUVATM Commercial Launch Progressing Ahead of Schedule Regulatory Filings	2023-05-01	English
Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule Regulatory Filings	2023-05-01	English
Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders AGM Information	2023-04-28	English
Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders Declaration of Voting Results & Voting Rights Announcements	2023-04-28	English
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100 Regulatory Filings	2023-04-17	English
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100 Regulatory Filings	2023-04-17	English
Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update Earnings Release FY 2022	2023-04-14	English
Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update Earnings Release FY 2022	2023-04-14	English
Relief Therapeutics Announces Executive Leadership Team Change Board/Management Information	2023-04-05	English
Relief Therapeutics Announces Executive Leadership Team Change Board/Management Information	2023-04-05	English
Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders AGM Information	2023-04-04	English
Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders AGM Information	2023-04-04	English
Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board Board/Management Information	2023-04-03	English
Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board Board/Management Information	2023-04-03	English
Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023 Regulatory Filings	2023-03-22	English
Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023 Regulatory Filings	2023-03-22	English
Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting Regulatory Filings	2023-03-17	English
Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting Regulatory Filings	2023-03-17	English
Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe Regulatory Filings	2023-03-16	English
Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe Regulatory Filings	2023-03-16	English
Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVATM Regulatory Filings	2023-03-15	English
Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA™ Regulatory Filings	2023-03-15	English
Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars Environmental & Social Information	2023-02-28	English
Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars Regulatory Filings	2023-02-28	English
Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis Bullosa Regulatory Filings	2023-02-14	English
Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis Bullosa Regulatory Filings	2023-02-14	English
Relief Therapeutics Provides an Update on its Financing Strategy Capital/Financing Update	2023-02-08	English
Relief Therapeutics Provides an Update on its Financing Strategy Share Issue/Capital Change	2023-02-08	English
Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphoma Regulatory Filings	2023-01-17	English
Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom Regulatory Filings	2023-01-17	English